LAS VEGAS — In this Healio Video Perspective from Clinical Trials at the Summit, SriniVas R. Sadda, MD, FARVO, discusses the challenges of using the ellipsoid zone as a trial endpoint.
“It is exciting that the FDA at least has indicated that the status of the photoreceptors, their preservation over time, is an important endpoint for trials, but they didn’t really get into the weeds about how do we actually measure it,” he said.
{{VIDEO}}
According to Sadda, challenges with using the ellipsoid zone (EZ) include inconsistent terminology for EZ (Read more...)